



## **Shareholder Update - 21 December 2023**

### **PharmaZen confirms continuing second half improvements.**

As indicated at the release of our Q3 result, we are pleased to provide an update on the performance of the company for the current quarter.

The trading improvements seen in Q2 and Q3 continue into Q4 for which we are forecasting another pleasing result. We are not forecasting Q4 to hit the same underlying EBITDA that we achieved in Q3 given the shorter trading month in December and year end cut-off issues, but we are still expecting to show a very favourable result for the quarter.

The Board wishes to thank all our shareholders and staff for their support over the year and are looking forward to continued growth and opportunities into 2024 and beyond.

Wishing everyone safe and happy holiday season.

Ken Fergus (Chairman)

### **Further information:**

Craig McIntosh

Managing Director

PharmaZen +64 21 372 069

### **About PharmaZen:**

PharmaZen (USX.PAZ), which trades as Waitaki Biosciences, is an innovative developer, manufacturer and marketer of science-based, natural, nutritional ingredients and consumer goods. Originally founded in Dunedin, PharmaZen now has the largest solvent extraction facility in the country and operates the largest batch freeze dryer in Australasia. Shares in PharmaZen are traded through the Unlisted securities trading platform.

---

Waitaki Biosciences a div. of PharmaZen Limited

P.O. Box 19-727 | Woolston | Christchurch | 3 Desi Place | Hillsborough 8022 | Christchurch  
P : +64-3-337-6096 | F : +64-3-337-4859 | E : [craig@waitakibio.co.nz](mailto:craig@waitakibio.co.nz) W : [www.waitakibio.co.nz](http://www.waitakibio.co.nz)